NCT07605091

Brief Summary

This study will assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplish by conducting a randomized, controlled dietary intervention study enrolling breastfeeding mothers and their newborn infants. Mothers will be randomized to receive either 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months, with follow-up for 2 years. Women must be \>18 years of age, ≤ 30 days postpartum and exclusively breastfeeding at the time of enrollment. Infants must be at least 37 weeks of gestational age, be healthy and are able to feed orally and consume human milk. After randomization and enrollment, breast milk samples will be obtained at baseline, 2, 4, and 6 months. Serum from mothers will be collected at recruitment, 2, 6,and 9 months; infant serum will be collected by capillary sample at recruitment and approximately at 4, 6, 12, 18, and 24 months. Infant hemoglobin and infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months. 24-hour dietary recall: the foods and drinks consumed by mothers in the 24 hours prior to each milk sample. Other assessments will include perceptions of breastfeeding, assess complementary feeding practices. Review will be conducted of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
44mo left

Started Nov 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 14, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 22, 2026

Completed
5 months until next milestone

Study Start

First participant enrolled

November 1, 2026

Expected
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2029

9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2030

Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

2.8 years

First QC Date

May 14, 2026

Last Update Submit

May 19, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Maternal Serum Levels of Estradiol

    Baseline, 2 months, 4 months, 6 months and 9 months

  • Maternal Serum Levels of Progesterone

    Baseline, 2 months, 4 months, 6 months, and 9 months

  • Maternal Serum Levels of Prolactin

    Baseline, 2 months, 4 months, 6 months, and 9 months

Study Arms (2)

Carrier and Moringa Leaf Powder

EXPERIMENTAL
Dietary Supplement: Moringa Leaf Powder

Carrier

PLACEBO COMPARATOR
Other: Carrier

Interventions

Moringa Leaf PowderDIETARY_SUPPLEMENT

Participants randomized to Moringa will consume 10 grams each day of the Moringa leaf powder mixed into porridge.

Carrier and Moringa Leaf Powder
CarrierOTHER

Participants randomized to the control will be given porridge without Moringa.

Carrier

Eligibility Criteria

Age7 Days - 99 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Infants: must be born at term (=37-42 weeks), singleton birth, breastfeeding, age 7-21 days at enrollment

You may not qualify if:

  • Mothers - women reporting regular consumption of moringa in the last month (\>1 time weekly), unable to consume moringa or unable to complete study activities within the first two weeks.
  • Mothers - Women with a contraindication to Moringa use (blood thinners, levothyroxine, antihypertensive treatments, insulin dependency).
  • Infants - significant congenital disease, are unable to feed orally.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SUNDY Downstate

Brooklyn, New York, 11203, United States

Location

MeSH Terms

Conditions

Breast Feeding

Interventions

Carrier State

Condition Hierarchy (Ancestors)

Feeding BehaviorBehavior

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsPublic HealthEnvironment and Public Health

Central Study Contacts

Philip Kern

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 14, 2026

First Posted

May 22, 2026

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

June 1, 2030

Last Updated

May 22, 2026

Record last verified: 2026-05

Locations